Companies

GSK looks to new chapter

FT pharmaceuticals correspondent Andrew Ward and Lex editor Robert Armstrong discuss whether GlaxoSmithKline can ease shareholder concerns and move into a new chapter following the bribery scandal in China and a decline in its share price in the past year.